These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 2994404)

  • 1. The design and properties of N-carboxyalkyldipeptide inhibitors of angiotensin-converting enzyme.
    Patchett AA; Cordes EH
    Adv Enzymol Relat Areas Mol Biol; 1985; 57():1-84. PubMed ID: 2994404
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical pharmacokinetics of the angiotensin converting enzyme inhibitors. A review.
    Kubo SH; Cody RJ
    Clin Pharmacokinet; 1985; 10(5):377-91. PubMed ID: 2994938
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacology of angiotensin converting enzyme inhibitors. A review.
    Nelson EB; Pool JL; Taylor AA
    Am J Med; 1986 Oct; 81(4C):13-8. PubMed ID: 3022580
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The chemistry of enalapril.
    Patchett AA
    Br J Clin Pharmacol; 1984; 18 Suppl 2(Suppl 2):201S-207S. PubMed ID: 6085275
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of angiotensin converting enzyme by 2-[N-[(S)-1-carboxy-3-phenylpropyl]-L-alanyl]-(1S,3S,5S)-2-azabicyclo [3.3.0]octane-3-carboxylic acid (Hoe 498 diacid). Comparison with captopril and enalaprilat.
    Bünning P
    Arzneimittelforschung; 1984; 34(10B):1406-10. PubMed ID: 6097266
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A comparison of the effects of two angiotensin converting enzyme inhibitors, SQ 14 225 and MK 422 in Na-restricted sheep.
    Nelson MA; Stewart KW; Coghlan JP; Denton DA; Fei DT; Scoggins BA
    Clin Exp Pharmacol Physiol Suppl; 1982; 7():87-91. PubMed ID: 6183038
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of SQ29,852, a new angiotensin converting enzyme (ACE) inhibitor with a phosphonic acid group, on the activity of angiotensin converting enzyme from human kidney.
    Hiwada K; Inoue Y; Kokubu T
    Gen Pharmacol; 1990; 21(4):555-8. PubMed ID: 2165961
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structural details on the binding of antihypertensive drugs captopril and enalaprilat to human testicular angiotensin I-converting enzyme.
    Natesh R; Schwager SL; Evans HR; Sturrock ED; Acharya KR
    Biochemistry; 2004 Jul; 43(27):8718-24. PubMed ID: 15236580
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Conformationally restricted inhibitors of angiotensin converting enzyme: synthesis and computations.
    Thorsett ED; Harris EE; Aster SD; Peterson ER; Snyder JP; Springer JP; Hirshfield J; Tristram EW; Patchett AA; Ulm EH
    J Med Chem; 1986 Feb; 29(2):251-60. PubMed ID: 3005569
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of angiotensin converting enzyme by [3H]captopril binding.
    Strittmatter SM; Snyder SH
    Mol Pharmacol; 1986 Feb; 29(2):142-8. PubMed ID: 3005826
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of rabbit lung angiotensin-converting enzyme by N alpha-[(S)-1-carboxy-3-phenylpropyl]L-alanyl-L-proline and N alpha-[(S)-1-carboxy-3-phenylpropyl]L-lysyl-L-proline.
    Bull HG; Thornberry NA; Cordes MH; Patchett AA; Cordes EH
    J Biol Chem; 1985 Mar; 260(5):2952-62. PubMed ID: 2982845
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The two homologous domains of human angiotensin I-converting enzyme interact differently with competitive inhibitors.
    Wei L; Clauser E; Alhenc-Gelas F; Corvol P
    J Biol Chem; 1992 Jul; 267(19):13398-405. PubMed ID: 1320019
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hormonal and metabolic effects of angiotensin converting enzyme inhibitors. Possible differences between enalapril and captopril.
    Atlas SA; Case DB; Yu ZY; Laragh JH
    Am J Med; 1984 Aug; 77(2A):13-7. PubMed ID: 6089554
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of renin and converting enzyme inhibition in sodium-deficient dogs.
    Blaine EH; Nelson BJ; Seymour AA; Schorn TW; Sweet CS; Slater EE; Nussberger J; Boger J
    Hypertension; 1985; 7(3 Pt 2):I66-71. PubMed ID: 2987127
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacological properties of the new non-sulfhydryl angiotensin converting enzyme inhibitor N-[8-amino-1(S)-carboxyoctyl]-L-alanyl-L-proline.
    Shirota M; Kajiwara Y; Iijima M; Kitabatake K
    Arzneimittelforschung; 1990 May; 40(5):515-9. PubMed ID: 2166521
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Carboxyl-terminal tripeptidyl hydrolysis of substance P by purified rabbit lung angiotensin-converting enzyme and the potentiation of substance P activity in vivo by captopril and MK-422.
    Cascieri MA; Bull HG; Mumford RA; Patchett AA; Thornberry NA; Liang T
    Mol Pharmacol; 1984 Mar; 25(2):287-93. PubMed ID: 6199659
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of N-[(S)-1-carboxy-3-phenylpropyl]-L-Ala-L-Pro and its ethyl ester (MK-421) on angiotensin converting enzyme in vitro and angiotensin I pressor responses in vivo.
    Gross DM; Sweet CS; Ulm EH; Backlund EP; Morris AA; Weitz D; Bohn DL; Wenger HC; Vassil TC; Stone CA
    J Pharmacol Exp Ther; 1981 Mar; 216(3):552-7. PubMed ID: 6259322
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development and design of specific inhibitors of angiotensin-converting enzyme.
    Cushman DW; Cheung HS; Sabo EF; Ondetti MA
    Am J Cardiol; 1982 Apr; 49(6):1390-4. PubMed ID: 6176105
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Angiotensin II-mediated vasoconstriction in chronic congestive heart failure, and response to converting enzyme inhibition.
    Cody RJ
    Am J Med; 1984 Aug; 77(2A):71-7. PubMed ID: 6089559
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of rabbit lung angiotensin converting enzyme by idrapril.
    Lippi A; Criscuoli M; Sardelli G; Subissi A
    Biochem Pharmacol; 1993 Mar; 45(6):1358-62. PubMed ID: 8385462
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.